Your browser doesn't support javascript.
loading
AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
Kavanagh, Simon; Heath, Emily; Hurren, Rose; Gronda, Marcela; Barghout, Samir H; Liyanage, Sanduni U; Siriwardena, Thirushi P; Claudio, Jaime; Zhang, Tong; Sukhai, Mahadeo; Stockley, Tracy L; Kamel-Reid, Suzanne; Rostom, Amr; Lutynski, Andrzej; Khalaf, Dina; Rydlewski, Anna; Chan, Steven M; Gupta, Vikas; Maze, Dawn; Sibai, Hassan; Schuh, Andre C; Yee, Karen; Minden, Mark D; Schimmer, Aaron D.
Afiliação
  • Kavanagh S; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Heath E; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Hurren R; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Gronda M; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Barghout SH; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Liyanage SU; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Siriwardena TP; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Claudio J; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Zhang T; Advanced Molecular Diagnostic Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Sukhai M; Advanced Molecular Diagnostic Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Stockley TL; Advanced Molecular Diagnostic Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, Universi
  • Kamel-Reid S; Advanced Molecular Diagnostic Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, Universi
  • Rostom A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Lutynski A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Khalaf D; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Rydlewski A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Chan SM; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Gupta V; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Maze D; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Sibai H; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Schuh AC; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Yee K; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Schimmer AD; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Electronic address: aaron.schimmer@utoronto.ca.
Leuk Res ; 68: 22-28, 2018 05.
Article em En | MEDLINE | ID: mdl-29518628
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vidarabina / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia de Indução Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vidarabina / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia de Indução Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá